Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill & Intangibles (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Goodwill & Intangibles for 11 consecutive years, with $43.6 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 12.77% to $43.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 million through Dec 2025, down 12.77% year-over-year, with the annual reading at $42.2 million for FY2025, 40.95% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $43.6 million at Aytu Biopharma, up from $41.4 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $151.3 million in Q2 2021, with the low at $41.4 million in Q3 2025.
  • Average Goodwill & Intangibles over 5 years is $74.8 million, with a median of $66.4 million recorded in 2021.
  • The sharpest move saw Goodwill & Intangibles skyrocketed 262.95% in 2021, then crashed 53.77% in 2022.
  • Over 5 years, Goodwill & Intangibles stood at $140.6 million in 2021, then plummeted by 53.77% to $65.0 million in 2022, then fell by 14.27% to $55.7 million in 2023, then decreased by 10.33% to $50.0 million in 2024, then decreased by 12.77% to $43.6 million in 2025.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $43.6 million, $41.4 million, and $42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.